Orphazyme AS (CHIX:ORPHAC) Ending Cash Position : kr49.53 Mil (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Ending Cash Position?

Orphazyme AS's Ending Cash Position for the quarter that ended in Jun. 2022 was kr49.53 Mil.

Orphazyme AS's quarterly Ending Cash Position declined from Jun. 2021 (kr334.18 Mil) to Dec. 2021 (kr102.26 Mil) and declined from Dec. 2021 (kr102.26 Mil) to Jun. 2022 (kr49.53 Mil).

Orphazyme AS's annual Ending Cash Position increased from Dec. 2019 (kr123.59 Mil) to Dec. 2020 (kr726.93 Mil) but then declined from Dec. 2020 (kr726.93 Mil) to Dec. 2021 (kr102.26 Mil).

Orphazyme AS Ending Cash Position Historical Data

The historical data trend for Orphazyme AS's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Ending Cash Position Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Ending Cash Position

Get a 7-Day Free Trial

631.74

394.71

123.59

726.93

102.26

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Ending Cash Position	Get a 7-Day Free Trial									610.45	726.93	334.18	102.26	49.53

Orphazyme AS Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Orphazyme AS's Ending Cash Position for the fiscal year that ended in Dec. 2021 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	726.929	+	-624.674
	=	102.26

Orphazyme AS's Ending Cash Position for the quarter that ended in Jun. 2022 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	165.832	+	-116.3
	=	49.53

Orphazyme AS Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines